

BSE SENSEX 72,772
S&P CNX 22,780



Bloomberg	SAGILITY IN
Equity Shares (m)	4681
M.Cap.(INRM)/(USDm)	203.4 / 2.1
52-Week Range (INR)	58 / 36
1, 6, 12 Rel. Per (%)	0/4/8
12M Avg Val (INR M)	1676

Financials Snapshot (INR m)

Y/E MARCH	FY26	FY27E	FY28E
Sales	71,929	88,089	102,009
Sales Gr. (%)	29.1	22.5	15.8
EBITDA	17,570	20,668	24,833
EBITDA Margin (%)	24.4	23.5	24.3
Reported PAT	9,248	11,158	14,022
EPS (Rs)	1.98	2.35	3.00
EPS Gr. (%)	68.9	19.0	27.4
BV/Share	20.6	22.8	25.5

Ratios

RoE	10.3	10.8	12.4
RoCE	12.4	13.6	15.4
RoIC	10.1	11.3	13.5


Valuations

EV/Sales	2.8	2.2	1.8
EV/EBITDA	11.6	9.4	7.5
P/E (X)	21.3	17.9	14.0
P/BV (X)	2.0	1.8	1.6

Shareholding pattern (%)

As On	Jun-26	Mar-26	Jun-25
Promoter	51.0	51.0	67.4
FII	21.4	22.3	14.1
DII	10.0	10.0	6.0
OthersPublic	17.6	16.7	12.6

Stock's performance (one-year)



CMP: INR43

TP: INR54 (+24%)

Buy

Higher MLR among US payers accelerating outsourcing

- Sagility's practices are designed to manage and improve critical healthcare operations across the payer and provider ecosystem. These capabilities span the full healthcare value chain, combining deep domain expertise with operational execution to deliver measurable outcomes.
- Services further advance through consulting and technology services, including assessments, transformation programs, platform enablement, and AI-led orchestration.
- **Member LCM:** It supports end-to-end member journey, including enrolment, billing, reconciliation, benefits management and ongoing engagement. This helps payers improve accuracy and timeliness, reduce revenue leakage and improve member experience.
- **Clinical (UM/CM):** It includes utilization management, case management, disease programs, and quality initiatives. These services deliver better care coordination and improved clinical and financial outcomes for our payer and provider clients.
- **Payment integrity (PI):** It focuses on identifying, preventing, and recovering inappropriate payments across the claim's lifecycle. This helps payers reduce leakage and gain better financial control.
- **Claims management:** It encompasses intake, adjudication support, rework, and appeals. These services enable payers to improve claims accuracy, reduce turnaround times, enhance operational efficiency and improve provider and member engagement.
- **Provider RCM:** It supports providers in billing, coding, denial management, and collections to improve revenue realization and cash flow performance.

We like Sagility's integrated approach of moving beyond isolated process execution toward managing connected workflows and delivering measurable outcomes across healthcare operations. This differentiated model creates a strong right to win vs. peers in capturing incremental business from payers. Its key strength lies in its ability to scale up efficiently, maintain exceptional attention to detail, and consistently deliver high-quality outcomes while meeting turnaround time requirements.

Valuation and view

We believe FY27 will be the year of growth normalization, considering a high base of FY26. We expect Sagility to deliver low double-digit growth, with broadly stable margins in the current range. We believe new logo additions, cross-selling opportunities and synergy from acquisitions will drive a CAGR of 19%/19%/23% in revenue/EBITDA/PAT over FY26-28. Accordingly, we reiterate our BUY rating on the stock with a TP of INR54 (based on 18x on FY28E EPS).

Exhibit 1: Client metrics

Y/E March	FY24	FY25	FY26
Client groups contribution to revenues	573	659	814
Top 3 client USD Revenue	390	435	488
YoY growth (%)	4%	12%	12%
% Contribution	68%	66%	60%
Top 5 client USD Revenue	453	514	570
YoY growth (%)	8%	14%	11%
% Contribution	79%	78%	70%
Top 10 client USD Revenue	521	600	684
YoY growth (%)	11%	15%	14%
% Contribution	91%	91%	84%

Exhibit 2: Continued expansion within top accounts, with significant headroom for wallet share gains and cross-selling

Top Accounts	Member LCM	Provider LCM	Claims Management	Clinical UM/CM	Payment Integrity
Client 1	○	●	●	○	○
Client 2	○	●	○	○	○
Client 3	○	●	●	○	○
Client 4	○	○	○	○	○
Client 5	○	○	○	○	○
Client 6	○	○	○	○	○
Client 7	○	○	○	○	○

Source: Company, MOFSL

Exhibit 3: Key partners

Strategic Platform Partners	 Availity  convey  HealthAxis  Elligint Health  Simplify Healthcare
SI Partners	 Deloitte.  EMIDS  infinite  CitiusTech
Capabilities Partners	 Optum  AUTOMATION ANYWHERE
Hyperscale Partners	 aws  Azure

Source: Company, MOFSL

Managed Services Model

- This model helps healthcare organizations to move beyond fragmented outsourcing relationships toward integrated, outcome-driven operating models.
- It follows structured assessment of operational performance across critical workforce such as enrollment, claims administration, care management, provider operations and payment processes.
- Sagility identifies inefficiencies, cost leakage, and opportunities for standardization, automation and improved decision-making.
- It deploys an integrated operating model that combines domain expertise, operational execution, technology and AI to deliver measurable outcomes.
- Clients approach Sagility to redesign workflows and embed AI directly into day-to-day operations to improve accuracy, speed and consistency.
- Emphasis includes capabilities such as workflow transformation, automation, analytics, clinical decision support, and the orchestration of interconnected processes across the healthcare value chain.
- Sagility uses elements to drive tangible impact, including cost reduction, quality improvement, faster turnaround times, and enhanced member and provider experiences.
- Notably, engagements are increasingly structured around performance, aligning Sagility's success directly with clients' improved outcome, which shifts relationships from transactional execution to shared ownership of outcomes.

We believe managed services model enables clients to simplify vendor ecosystems, modernize, legacy workflows, and transition from effort-based operating approaches to more scalable and outcome-oriented models.

Medical loss ratio (MLR) reduction solutions

- MLR reduction solutions are designed to help healthcare organizations manage and reduce medical costs while improving outcome quality across the care continuum.
- Solutions focus on high-impact areas such as utilization management, care coordination, clinical review, and quality improvement programs.
- In these applications, the use of analytics and AI, which enables risk scoring, more accurate clinical decision-making, and better intervention timing, significantly influences medical cost and health outcomes, with the same or lower operational spending.
- The approach integrates Sagility's domain expertise, data scientists specializing in payer-clinical data analytics, at-scale clinical services, operational excellence, and technology to improve precision in key workflows, including prior authorization, case management, and ongoing utilization monitoring.
- By embedding intelligence into these processes, Sagility enables more consistent application of clinical guidelines, earlier identification of risk, and proactive intervention.

Rising MLRs among leading US payers, including UHC, Humana, CVS Aetna, Elevance, Cigna Healthcare and Centene, are putting continued pressure on margins, potentially driving greater outsourcing to improve cost efficiency.

Financials and Valuation

Consolidated - Income Statement

(INR Million)

Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	42,184	47,536	55,699	71,929	88,089	102,009
Change (%)		12.7	17.2	29.1	22.5	15.8
Employees Cost	24,942	29,376	34,989	45,103	55,060	63,689
Gross Profit	17,242	18,159	20,710	26,826	33,029	38,320
Margin (%)	40.9	38.2	37.2	37.3	37.5	37.6
Other Expenses	6,970	7,278	7,731	9,256	12,361	13,488
Total Expenditure	31,912	36,655	42,720	54,359	67,421	77,177
% of Sales	75.6	77.1	76.7	75.6	76.5	75.7
EBITDA	10,272	10,881	12,979	17,570	20,668	24,833
Margin (%)	24.4	22.9	23.3	24.4	23.5	24.3
Depreciation	6,443	6,892	4,669	4,874	5,730	6,631
EBIT	3,829	3,989	8,310	12,697	14,939	18,202
Margin (%)	9.1	8.4	14.9	17.7	17.0	17.8
Int. and Finance Charges	2,148	1,851	1,271	992	876	400
Other Income	177	279	563	1,013	828	1,020
PBT bef. EO Exp.	1,857	2,417	7,602	12,718	14,891	18,822
EO Items	0	0	0	-328	0	0
PBT after EO Exp.	1,857	2,417	7,602	12,389	14,891	18,822
Total Tax	421	134	2,211	3,141	3,732	4,800
Tax Rate (%)	22.7	5.6	29.1	25.4	25.1	25.5
Reported PAT	1,436	2,283	5,391	9,248	11,158	14,022
Adjusted PAT	4,684	5,896	8,106	11,306	12,792	15,739
Change (%)		25.9	37.5	39.5	13.1	23.0
Margin (%)		12.4	14.6	15.7	14.5	15.4

Consolidated - Balance Sheet

(INR Million)

Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	19,187	42,853	46,793	46,793	46,793	46,793
Total Reserves	42,880	21,578	36,568	49,798	59,705	72,325
Net Worth	62,067	64,431	83,361	96,591	106,498	119,118
Total Loans	23,237	16,647	5,670	0	0	0
Other Non-Current Liabilities	15,999	20,853	17,197	25,209	22,166	27,715
Deferred Tax Liabilities	4,602	4,710	4,279	4,211	4,211	4,211
Capital Employed	105,905	106,642	110,507	126,011	132,875	151,044
Gross Block	3,932	5,787	6,397	8,590	11,268	14,364
Less: Accum. Deprn.	977	1,955	2,698	4,359	6,295	8,455
Net Fixed Assets	2,955	3,832	3,699	4,231	4,973	5,909
CWIP	3	57	0	393	393	393
Right-of-use asset	5,295	5,665	5,521	4,868	4,868	4,868
Intangible assets	23,221	20,078	20,362	20,370	20,370	20,370
Goodwill	54,598	57,096	60,390	64,051	64,051	64,051
Other Non-Current Assets	1,899	2,714	2,326	2,615	2,615	2,615
Curr. Assets, Loans&Adv.	17,934	17,199	18,208	29,445	35,567	52,802
Account Receivables	6,376	7,400	8,637	18,390	22,903	30,603
Cash and Bank Balance	5,853	3,441	3,438	3,579	7,288	16,823
Other Current Assets	5,705	6,358	6,133	7,476	5,376	5,376
Curr. Liability & Prov.	10,564	14,521	10,891	18,975	15,932	21,481
Account Payables	2,135	2,593	2,136	2,217	2,715	3,144
Other Current Liabilities	7,702	11,255	7,803	15,396	11,855	16,975
Provisions	727	673	952	1,363	1,363	1,363
Net Current Assets	7,370	2,678	7,317	10,470	19,635	31,320
Appl. of Funds	105,905	106,642	110,507	126,011	132,875	151,044

E: MOFSL Estimates

Financials and Valuation

Ratios

Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)						
EPS	0.3	0.5	1.2	2.0	2.4	3.0
Cash EPS	2.6	3.0	2.7	3.4	4.0	4.8
BV/Share	14.5	15.0	17.8	20.6	22.8	25.5
DPS	0.0	0.0	0.0	0.2	0.2	0.3
Payout (%)	0.0	0.0	0.0	10.0	10.0	10.0
Valuation (x)						
P/E	125.4	78.9	35.9	21.3	17.9	14.0
Cash P/E	18.5	16.1	17.6	14.1	12.1	10.0
P/BV	2.9	2.8	2.4	2.0	1.8	1.6
EV/Sales	4.8	4.2	3.7	2.8	2.2	1.8
EV/EBITDA	19.8	18.6	16.0	11.6	9.4	7.5
Dividend Yield (%)	0.0	0.0	0.0	0.1	0.5	0.6
FCF per share	1.6	1.1	0.5	2.2	2.2	2.1
Return Ratios (%)						
RoE	2.8	3.6	7.3	10.3	10.8	12.4
RoCE	4.3	4.4	8.9	12.4	13.6	15.4
RoIC	3.7	4.7	7.0	10.1	11.3	13.5
Working Capital Ratios						
Fixed Asset Turnover (x)	15.0	14.0	14.8	18.1	19.1	18.7
Asset Turnover (x)	0.4	0.4	0.5	0.6	0.7	0.7
Debtor (Days)	53	53	53	52	51	51
Creditor (Days)	24	29	25	18	16	17
Leverage Ratio (x)						
Current Ratio	1.7	1.2	1.7	1.6	2.2	2.5
Interest Cover Ratio	1.8	2.2	6.5	12.8	17.1	45.5
Net Debt/Equity	0.4	0.2	0.2	0.0	0.0	0.0

E: MOFSL Estimates

Consolidated - Cash Flow Statement

Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
Profit before Tax	1,857	2,417	7,602	12,389	14,740	18,822
Depreciation & Amortisation	6,443	6,892	4,669	4,874	5,730	6,631
Net Interest Exp. /Inc.(-)	16	-109	-237	-187	-828	-1,020
Inc(-)/Dec in WC	-704	-114	-710	-1,895	-4,015	-7,271
Others	2,654	1,910	2,550	584	876	400
Taxes paid	-1,698	-1,263	-1,734	-3,735	-3,732	-4,800
Operating Cash Flow	8,568	9,733	12,141	12,030	12,770	12,762
Capex	-1,576	-4,834	-9,805	-1,917	-2,643	-3,060
Free Cash Flow	6,991	4,899	2,336	10,113	10,128	9,702
Inc(-)/Dec in Investments	0	0	0	-5,370	0	0
Others	10	25	159	180	0	0
Investing Cash Flow	-1,291	-4,691	-9,642	-7,107	-2,643	-3,060
Inc/Dec (-) Capital	0	-72	0	0	0	0
Dividend + Tax thereon	0	0	0	-234	0	0
Inc/Dec (-) Loans	-4,035	-5,764	-4,567	-2,937	-6,651	-400
Others	-1,411	-1,677	-1,774	-1,843	0	0
Financing Cash Flow	-5,446	-7,513	-2,561	-5,014	-6,651	-400
Inc/Dec (-) Cash	1,831	-2,471	-62	-91	3,476	9,302
Opening Cash Balance	3,738	5,853	3,441	3,438	3,579	7,288
Closing Cash Balance	5,853	3,441	3,438	3,579	7,288	16,823

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	$\geq 15\%$
SELL	$< -10\%$
NEUTRAL	$< -10\%$ to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.